This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… platform for the exchange and sharing of insights and innovations to drive the future of clinical development in … platform for the exchange and sharing of insights and innovations to drive the future of clinical development in …
Axiomer platform presentation highlighting the potential of Editing Oligonucleotides (EONs) to address liver originated disorders. Presented at the RNA Editing Gordon Research Conference on March 23, 2023 by Gerard Platenburg - ProQR Therapeutics.
… of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our … developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration. Andrew C. …
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … in the lab and play a key role in translating scientific innovation into practical applications. You will …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … applied clinical quantitative sciences and a passion for innovation in drug development. Location: Leiden, NL Key …
